Human immunodeficiency virus type 1 Gag-Pol polyprotein (HIV-1 Gag-Pol) (HIV-1 Gag-Pol)

The HIV-1 Gag-Pol polyprotein is a critical precursor protein required for the replication and maturation of the Human Immunodeficiency Virus type 1 (UniProt P03366). It is produced through a programmed -1 ribosomal frameshift during the translation of the gag gene, resulting in a fusion protein that includes the structural components of Gag and the enzymatic components of Pol (PubMed, PMID: 15522470). The Pol segment encodes three essential enzymes: Protease, Reverse Transcriptase, and Integrase, which are responsible for processing viral proteins, converting viral RNA into DNA, and integrating that DNA into the host genome, respectively (NIH, 2023). Because these enzymes are vital for the viral life cycle, they serve as the primary targets for most antiretroviral therapies (ART). Inhibition of these processes, such as through protease inhibitors, prevents the formation of infectious progeny and reduces the viral load in infected individuals (PubChem). Additionally, newer classes of drugs like capsid inhibitors target the Gag-derived capsid protein to disrupt viral assembly and nuclear entry (Nature, 2020). However, the high mutation rate of HIV-1 often leads to the emergence of drug-resistant variants, necessitating the use of combination therapy to maintain long-term viral suppression (StatPearls, 2023). This polyprotein system is thus central to both the pathophysiology of AIDS and the pharmacological strategies used to combat the infection.

Other names

Pr160Gag-PolGag-Pol polyproteinHIV-1 Gag-Pol fusion proteinP160 polyproteinGag-polyprotein

Drugs targeting the Gag-Pol polyprotein components function by inhibiting the viral protease (preventing polyprotein cleavage and virion maturation), reverse transcriptase (blocking RNA-to-DNA conversion), or integrase (preventing viral DNA insertion into the host genome). Additionally, capsid inhibitors target the Gag-derived capsid protein to disrupt viral assembly and nuclear transport (NIH, 2023; Nature, 2020).